US-BASED clinical technology company InterVenn Bioscience has established Malaysia as the regional hub for the delivery of its medical healthcare services and products in the ASEAN and Asia Pacific regions.
The company’s key services and products are involved in research and development, and revolutionising the fight against cancers and diseases through deployment of emerging technologies such as artificial intelligence (AI), spectrometry and machine learning (ML) algorithms to help cancer patients, doctors, scientists and healthcare community.
Preparing Malaysia to be the regional hub, InterVenn Biosciences – a top-prize winner of the prestigious CIO Review APAC Top Artificial Intelligence Company Award 2022 – has secured a new 13,000 sq ft office and laboratory located at Technology Park Malaysia, Kuala Lumpur.
The laboratory, outfitted with state-of-art equipment, is the only other InterVenn laboratory outside of the US.
This facility provides an opportunity to tap into and grow the locally based, biomedical talent in Malaysia.
According to InterVenn CEO and co-founder Aldo Carrascoso, the key decisions in selecting Malaysia also lies in his vision to be closer with the patients and experts in the region to accelerate the mission that no one should be blindsided by the disease.
“Here at InterVenn, maladies are holistically understood, adequately controlled and even manipulated to benefit all,” he elaborated.
“We exist today to revisit the health-disease spectrum with an unprecedented and exclusive focus on ‘glyco’ while incorporating the latest technological advancements and fully supporting our Malaysian office with those tools.”
Meanwhile, InterVenn Malaysia general manager Fadzhairi Jabar noted that a part of this growth was the result of the support of regional collaborators and partners as well as recognition given by the relevant government agencies and research institutions.
“InterVenn was certified as part of Bioeconomy Corporation’s BBA programme last year, expanding and fostering this interaction as aligned with our vision towards creating a world where everyone in the region benefits from our goal,” he remarked.
Utilising AI, InterVenn Biosciences has developed a first-of-its-kind glycoproteomics-based liquid biopsy solution to detect and diagnose cancers.
Its AI-enabled mass spectrometry glycoproteomics platform enables researchers at academic centers and biopharmaceutical companies to assess post-translational modifications at an unprecedented scale and speed.
Currently, InterVenn Biosciences has a wide range of breakthrough tests for various types of cancers and diseases in the pipeline. InterVenn’s non-traditional approach to epi-proteomics is a marriage of mass spectrometry and AI/ML. – Aug 3, 2022
